THEMISMED.NSE · Themis Medicare Limited

-

Please sign in to comment on THEMISMED.NSE

1 Comment

Admin

4 years, 1 month ago

Themis Medicare Limited is currently in a long term uptrend where the price is trading 82.8% above its 200 day moving average.

From a valuation standpoint, the stock is 72.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.3.

Themis Medicare Limited's total revenue rose by 21.8% to $655M since the same quarter in the previous year.

Its net income has increased by 10.3% to $118M since the same quarter in the previous year.

Finally, its free cash flow grew by 487.1% to $313M since the same quarter in the previous year.

Based on the above factors, Themis Medicare Limited gets an overall score of 5/5.

Exchange	NSE
CurrencyCode	INR
ISIN	INE083B01024
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Beta	-0.07
PE Ratio	27.09
Target Price	None
Dividend Yield	0.4%
Market Cap	12B

ABOUT

Themis Medicare Limited

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. The company offers active pharmaceutical ingredients (APIs) and formulations for use in various therapeutic areas, including anti-tuberculosis, anti-malarials, cardiology, pain management, anti-infectives, haematinics, health and nutrition, anaesthesia, gynecology, and orthopedics. It also offers anti-inflammatory drugs and other drugs. The company was formerly known as Themis Chemicals and changed its name to Themis Medicare Limited in 2001. Themis Medicare Limited was founded in 1952 and is headquartered in Mumbai, India.

THEMISMED.NSE · Themis Medicare Limited

-

Themis Medicare Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Themis Medicare Limited using a moving average strategy